{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:08:14Z","timestamp":1767186494860,"version":"build-2238731810"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1532\/ijh97.07099","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T13:59:16Z","timestamp":1704203956000},"page":"208-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cytogenetic Remissions Induced by Interferon \u03b1 and Imatinib Mesylate are Immunologically Distinct in Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"86","author":[{"given":"Shin","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiko","family":"Nagamura-Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Uchimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"863208_CR1","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640\u20132653.","journal-title":"Blood"},{"key":"863208_CR2","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425\u20133432.","journal-title":"Clin Cancer Res."},{"key":"863208_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1532\/IJH97.04054","volume":"79","author":"G Borthakur","year":"2004","unstructured":"Borthakur G, Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004;79:411\u2013419.","journal-title":"Int J Hematol."},{"key":"863208_CR4","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u20132417.","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"863208_CR5","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","volume":"28","author":"MJ Mauro","year":"2004","unstructured":"Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28(Suppl 1):S71-S73.","journal-title":"Leuk Res."},{"key":"863208_CR6","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204\u20132205.","journal-title":"Blood"},{"key":"863208_CR7","first-page":"979","volume":"90","author":"S Merante","year":"2005","unstructured":"Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979\u2013981.","journal-title":"Haematologica."},{"key":"863208_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1196\/annals.1349.022","volume":"1044","author":"S Balabanov","year":"2005","unstructured":"Balabanov S, Appel S, Kanz L, Brossart P, Br\u00fcmmendorf TH. Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. Ann N Y Acad Sci. 2005;1044: 168\u2013177.","journal-title":"Ann N Y Acad Sci."},{"key":"863208_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473\u20132479.","journal-title":"Blood"},{"key":"863208_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","volume":"23","author":"S Appel","year":"2005","unstructured":"Appel S, Balabanov S, Br\u00fcmmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23:1082\u20131088.","journal-title":"Stem Cells."},{"key":"863208_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","volume":"103","author":"S Appel","year":"2004","unstructured":"Appel S, Boehmler AM, Gr\u00fcnebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood. 2004;103:538\u2013544.","journal-title":"Blood"},{"key":"863208_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","volume":"114","author":"M Talpaz","year":"1991","unstructured":"Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532\u2013538.","journal-title":"Ann Intern Med."},{"key":"863208_CR13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","volume":"79","author":"MS Lee","year":"1992","unstructured":"Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992;79:1920\u20131923.","journal-title":"Blood"},{"key":"863208_CR14","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018\u20131023.","journal-title":"Nat Med."},{"key":"863208_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jneuroim.2006.09.006","volume":"181","author":"M Krakauer","year":"2006","unstructured":"Krakauer M, Sorensen PS, Sellebjerg F. CD4+ memory T cells with high CD26 surface expression are enriched forTh1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol. 2006;181:157\u2013164.","journal-title":"J Neuroimmunol."},{"key":"863208_CR16","doi-asserted-by":"publisher","first-page":"L1564","DOI":"10.1152\/ajplung.00273.2006","volume":"292","author":"T Skripuletz","year":"2007","unstructured":"Skripuletz T, Schmiedl A, Schade J, et al. Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1564-L1571.","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"863208_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/sj.leu.2404522","volume":"21","author":"E Nadal","year":"2007","unstructured":"Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4+CD25high Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2007;21:472\u2013479.","journal-title":"Leukemia"},{"key":"863208_CR18","doi-asserted-by":"crossref","unstructured":"Cervetti G, Carulli G, Galimberti S, et al. Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. Leuk Res. 2007. In press.","DOI":"10.1016\/j.leukres.2007.02.013"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1532\/IJH97.07099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1532\/IJH97.07099\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1532\/IJH97.07099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:31:17Z","timestamp":1704205877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1532\/IJH97.07099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":18,"aliases":["10.1007\/bf03006921"],"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["863208"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.07099","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"6 June 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}